Heat Biologics Completes Rebranding to NightHawk Biosciences; Trading will begin under “NHWK” from market open today

DURHAM, NC, May 03, 2022 (GLOBE NEWSWIRE) — Heat BiologicsInc. / NightHawk Biosciences (US NYSE:HTBX; NHWK), a fully integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that it has completed its name change from Heat Biologics, Inc. to NightHawk Biosciences, Inc. to better reflect the evolution of the company, including the expansion of the therapeutic pipeline, the vertical integration of capabilities from drug discovery to manufacturing and commercialization, as well as the Company’s new biodefense capabilities. As part of the name change, the symbol of the Company will become “NHWK”, effective today, May 3, 2022. The name and symbol changes do not affect the share structure of the Company nor the rights of shareholders of the Company, and no further action is required by existing shareholders.

Jeff Wolf, CEO of Nighthawk, said, “The NightHawk brand better reflects our evolution towards a fully integrated ecosystem, designed to move medicines efficiently from discovery to commercialization. The NightHawk ecosystem includes an expanded development pipeline, new biodefense capabilities, and enhanced manufacturing capabilities. Accordingly, we have organized the Company around five main subsidiaries: Organic Skunkworx, Heating organic products, therapeutic pelican, Elusys Therapeutic and Scorpio Biological Services. NightHawk is focused on solving key industry challenges, including the slow and high cost of new drug development through a fully integrated ecosystem of drug discovery, preclinical testing and manufacturing. We look forward to advancing these efforts under the NightHawk banner. »

NightHawk Biosciences, Inc.
NightHawk Biosciences is a fully integrated biopharmaceutical company focused on the development of new drugs from discovery to commercialization. The Company relies on its integrated ecosystem of subsidiaries to accelerate the creation and manufacturing of new therapies that arm the immune system, breaking down the barriers that prolong the development of traditional drugs. This allows us to bring our ideas to life with effective control, superior quality and unusual agility.

For more information about the Company and its subsidiaries, please visit: www.nighthawkbio.comand also follow us on Twitter.

Forward-looking statement

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some instances, forward-looking statements may be identified by words such as “may”, “should”, “potential”, “continuing”, “expects”, “anticipates”, “intends”, “plans”, “believes”, “estimates” and similar expressions, and includes statements advancing the company’s efforts under the NightHawk banner. Important factors that could cause actual results to differ materially from current expectations include, among others, the ability to advance the company’s efforts under the NightHawk banner, the ability to complete to successfully integrate ongoing changes , that the combined businesses of NightHawk and Elusys will be successful, the ability of NightHawk and its subsidiaries to maintain licensing agreements, the continued maintenance and growth of NightHawk and its subsidiaries’ patent areas, NightHawk’s product candidates demonstrating their safety and efficacy, as well as results consistent with past results, the ability to initiate clinical trials and, if initiated, the ability to complete them on time and achieve the desired results and benefits the continuation of registration as expected, the ability to obtain regulatory approval for the commercialization of product candidates or e to comply with ongoing regulatory requirements, regulatory limitations relating to NightHawk ty’s ability to promote or commercialize its product candidates for the specific indications, market acceptance of the product candidates, and successful development, commercialization or sale of NightHawk, developments by competitors that render such products obsolete or uncompetitive, and other factors described in NightHawk’s annual report on Form 10-K for the fiscal year ended December 31, 2021, subsequent quarterly reports on Form 10-Q and any other documents filed by NightHawk with the SEC. The information in this presentation is provided only as of the date presented, and NightHawk undertakes no obligation to update any forward-looking statements contained in this presentation as a result of new information, future events or otherwise, except as required by law. ‘required.

Media Contact and Investor Relations
David Walman
+1 919 289 4017

[email protected]

main logo

Garland K. Long